Alchemab Therapeutics unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium

Posted on by

CAMBRIDGE, England, June 22, 2023 /PRNewswire/ — Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.